The Penarth headquartered firm has released a trading statement to the City
Penarth headquartered global point of care diagnostics firm EKF Diagnostics said it is on track for a stronger end to the year after posting first half numbers in line with management expectations, while confirming that cash levels held in Russia have risen.
In a trading statement the Alternative Investment Market listed firm that in the first half of this year revenues remained broadly flat at £25.m (H1 2025: £25.2m), reflecting the higher weighting of sales expected in the second half of the year. Gross margin improved to 53% (H1 2025: 50%) and adjusted Ebitda showed continued growth.
The group’s cash balance as at 30 June 2026 was £16 (31 December 2025: £15.8m), which included £2.4m held in Russia (31 December 2025: £2.1m).
It operates in Russia via its German-based subsidiary, in which it has a 60% stake, selling non sanctioned medical devices. However, since Russia’s invasion of Ukraine the Putin administration has put tight limits on the amount of cash from trading that foreign firms are able to move out of the country.
It is a counter measure to western sanctions. For the last two years EKF’s subsidiary has been able to release around £500,000 per annum in dividend payments. The rise in cash from £2.1m to £2.5m has in part been driven by improved exchange rates.
EKF has no bank borrowings, and the closing cash balance reflects the allocation of £1.4m for the ongoing share buyback programme, of which £900,000 has been deployed during the period, together with the continued investment for growth that is part of the five-year strategic development plan for the business.
It said: “The progress of the five-year strategy continues in line with management expectations. Diabetes and hematology delivered steady performances in the first half, with the majority of high-volume tenders already won and scheduled to be delivered in the historically stronger second half year.”
It added that its remains on track to deliver growth at the revenue and adjusted Ebitda levels for full year 2026 in line with current market expectations.
Following the trading statement brokers Singer, Stifel and Panmure Liberum all maintained their buy share positions. Panmure Liberum has a share price target of 34p with the other two slightly higher at 35p.
In its note Panmure Liberum said: “The shares are still cheap, and remain range bound with he buy-back providing a floor to the price.
“There is little in the statement to change this prior to the interims. However, the longer-term outlook remains more encouraging and we expect the growth rate to improve, margins to continue to expand and strong cash conversion. We retain our buy (share recommendation).
Shares in EKF fell slightly after the trading statement to around 25p.





You must be logged in to post a comment Login